STATEMENT
FAES FARMA and INVIDA (MENARINI Group) sign an agreement to commercialize bilastine in 17 countries in Asia - Pacific
Both companies have signed an agreement covering countries as
important as China and Australia, along with other relevant
markets such as Philippines, Vietnam, Thailand, Singapore,
Taiwan and Malaysia.
The region is one of the largest anti-histamine markets and
enjoys a double digit annual growth rate.
INVIDA is one of the commercially strongest pharmaceutical
companies in the region, with a sales and promotion force
exceeding 3.500 people.
Sales forecasts estimations shared by the two partners
estimate capturing an antihistamine market share of up to 15
%.
This agreement will reinforce the partnership between FAES
and MENARINI, group that recently has acquired INVIDA to
strengthen its presence in Asia.
With this license, FAES gives a key step in its strategy of
licensing bilastine to first class companies and building a
global presence for its allergy product bilastine.
According to this agreement, FAES FARMA will receive upfront
and milestone payments and will be the exclusive supplier of
the Active Ingredient to INVIDA.
April 26th, 2012
distributed by |